RAFARM S.A.

Pharmaceutical ManufacturingAttikí, Greece201-500 Employees

RAFARM S.A. is a Greek pharmaceutical manufacturer headquartered in Athens in the Attikí region. It is an innovation-driven, growth-oriented company and ranks among the larger players in Greece, with a broad international focus. The firm allocates 10% of its net turnover to research and development, maintaining a pipeline of more than 100 development products and developing about ten new products each year, supported by 40 active pharmaceutical technology projects annually and around 1,100 licensed formulations. The organization operates three production facilities and an independent Research Center with storage space, totaling 16,000 square meters, and is pursuing a €65 million investment program in Greece for 2021–2025. It has expanded exports to more than 60 countries, indicating a substantial outward footprint. 

It serves both domestic and international customers and continues to broaden its product portfolio. The company emphasizes capabilities in sterile and injectable forms and relies on its regulatory affairs and R&D expertise to bring products to market efficiently. A concrete development is the 2021 launch of a moxifloxacin ophthalmic solution in collaboration with Upsher-Smith, illustrating its activity in ophthalmic products and sterile manufacturing.

Sign up for free to view info

Email Format Employee directory